Big News Roundup: Relay Medical To Commence Trading in United States as RYMDF; BriaCell Announces Positive Phase IIa Proof of Concept Data in Advanced Breast Cancer; Initiates Combination Study; Kalytera Announces Progress with Cannabinoid-Based Compound for Treatment of Acute and Chronic Pain
pharmaceutical-investing 3D Signatures Strengthens Its Intellectual Property With New Patents Issued for Tests in Alzheimer’s Disease, Hodgkin’s Lymphoma and Multiple Myeloma
pharmaceutical-investing 3D Signatures Collaborates with MDxHealth to Evaluate Telo-PC™ Test in Prostate Cancer
3D Signatures and l’Institut Universitaire de Cardiologie et de Pneumologie de Québec Announce Collaboration
pharmaceutical-investing 3D Signatures Inc. and l’Institut Universitaire de Cardiologie et de Pneumologie de Québec (IUCPQ) Announce Collaboration to Combine TeloView™ with Genome Sequence Analysis in Lung Cancer
medical-device-investing 3D Signatures Announces Positive Topline Results of Development Trial Assessing its Telo-HL Test for Hodgkin’s Lymphoma
3D Signatures Inc. Announces Positive Topline Results of Development Trial Assessing its Telo-HL™ Test for Hodgkin’s Lymphoma
pharmaceutical-investing 3D Signatures Inc. Announces the Closing of its Non-Brokered Private Placement
pharmaceutical-investing 3D Signatures Inc. Announces Upsizing of $1,500,000 Private Placement, the Appointment of a New Director and Reports on AGM Results
3D Signatures Inc. Announces Non-Brokered Private Placement to Raise $1,500,000 and Updates Previously Announced Brokered Private Placement
